pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
209
stories
11d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
14d
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
biopharma dive
14d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
14d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
14d
Updated: BlossomHill, Latigo cap four-IPO week with combined $496M haul
endpoints
15d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
15d
STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more
stat
15d
Recon: FDA approves first drug for type 1 narcolepsy, mRNA flu vaccine; No merger talks between AstraZeneca-BMS
raps
16d
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
16d
STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more
stat
16d
Merger talks between AstraZeneca, Bristol Myers are off — report
endpoints
16d
A COPD drug from China draws $115M in venture funding
biopharma dive
16d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
17d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
17d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
17d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
17d
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
stat
17d
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
stat
17d
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
biospace
17d
Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?
endpoints
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
17d
Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E
endpoints
17d
STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
stat
17d
Biopharma industry questions potential AstraZeneca, Bristol Myers merger
endpoints
18d
Michigan reports the first 2 U.S. deaths related to a diarrhea-causing parasite
stat
18d
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
18d
STAT+: Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments
stat
18d
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
biospace
18d
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
stat
← prev
page 2 of 7
next →
